Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.

@article{Uriel2017HemocompatibilityRelatedOI,
  title={Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.},
  author={Nir Uriel and Paolo Colombo and Joseph Cleveland and James W Long and Christopher Salerno and Daniel J. Goldstein and Chetan B. Patel and Gregory A. Ewald and Antone J. Tatooles and Scott C. Silvestry and Ranjit John and Christiano Castello Branco Caldeira and Valluvan Jeevanandam and A. R. Boyle and Kartik Sundareswaran and Poornima R Sood and Mandeep R Mehra},
  journal={Circulation},
  year={2017},
  volume={135 21},
  pages={2003-2012}
}
BACKGROUND The HeartMate 3 (HM3) Left Ventricular Assist System (LVAS) (Abbott) is a centrifugal, fully magnetically levitated, continuous-flow blood pump engineered to enhance hemocompatibility and reduce shear stress on blood components. The MOMENTUM 3 trial (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) compares the HM3 LVAS with the HeartMate II (HMII) LVAS (Abbott) in advanced heart failure refractory to medical… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 41 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com